Clinical Trials Directory

Trials / Completed

CompletedNCT01504646

Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

Randomized Controlled Trial of Marine Lipid Fraction PCSO-524™ on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction in Asthma

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Indiana University · Academic / Other
Sex
All
Age
18 Years – 30 Years
Healthy volunteers
Not accepted

Summary

The primary aim of this study will be to evaluate the effects of Lyprinol® supplementation on airway inflammation and the bronchoconstrictor response to dry air hyperpnea in individuals with asthma. The investigators hypothesize that Lyprinol® supplementation, compared to placebo, will significantly attenuate airway inflammation and hyperpnea-induced bronchoconstriction in asthmatic individuals.

Detailed description

Our research group has shown, on numerous occasions that fish oil has a markedly protective effect in suppressing airway inflammation and exercise-induced bronchoconstriction in elite athletes and asthmatic individuals. Purified fish oil and the marine lipid fraction PCSO-524™ (Lyprinol™) have both been used in supplementation studies in asthma \[2, 10, 11\]. While fish oil is a rich source of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), Lyprinol® is a patented extract of stabilized lipids from the New Zealand green-lipped mussel, Perna canaliculus, combined with olive oil and vitamin E. EPA and DHA are the main ingredients of fish oil, and thus there will be similarities between Lyprinol and fish oil in terms of mechanism of action. Thus, we are aiming to show that Lyprinol® can modulate these inflammatory eicosanoids to exert anti-inflammatory effects.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTLyprinol8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
DIETARY_SUPPLEMENTPlacebo (Olive Oil)8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks

Timeline

Start date
2012-01-01
Primary completion
2012-08-01
Completion
2012-08-01
First posted
2012-01-05
Last updated
2018-10-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01504646. Inclusion in this directory is not an endorsement.